The Pharma 5: Washington knocks out wobbly D2C exception to worthy Learned Intermediary

This month, Jackie Karama, an associate in Los Angeles whose practice focuses on pharma disputes, discusses:

• Securities – clinical trials
• Consumer sales – standing
• FDA - NDA regulation
• Orphan Drug Act – exclusivity
• Learned Intermediary – D2C